Predictive value and cost-effectiveness analysis of a rapid polymerase chain reaction for preoperative detection of nasal carriage of Staphylococcus aureus

Infection Control and Hospital Epidemiology

Volumn 24, Issue 5, 2003, Pages 327-333

  Shrestha, Nabin K ^b   Shermock, Kenneth M ^b   Gordon, Steven M ^b   Tuohy, Marion J ^b   Wilson, Deborah A ^b   Cwynar, Roberta E ^b   Banbury, Michael K ^b   Longworth, David L ^b   Isada, Carlos M ^b   Mawhorter, Steven D ^b   Procop, Gary W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METICILLIN; PSEUDOMONIC ACID;

ACCURACY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM DETECTION; COST; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; FINANCIAL MANAGEMENT; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; NOSE SMEAR; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; PREDICTION; PREOPERATIVE PERIOD; PREVALENCE; STAPHYLOCOCCUS AUREUS; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; UNITED STATES;

ALGORITHMS; BASE SEQUENCE; CARRIER STATE; COST-BENEFIT ANALYSIS; DNA PRIMERS; HUMANS; MUPIROCIN; NASAL CAVITY; OHIO; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; PREVALENCE; SENSITIVITY AND SPECIFICITY; STAPHYLOCOCCUS AUREUS; THORACIC SURGICAL PROCEDURES;

EID: 0038624012     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502219     Document Type: Article

References (31)

1. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance (NNIS) report: data summary from October 1986-April 1996, issued May 1996. Am J Infect Control 1996;24:380-388.
2. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia: study group. N Engl J Med 2001;344:11-16.
3. Reagan DR, Doebbeling BN, Pfaller MA, et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991;114:101-106.
4. Wenzel RP, Perl TM. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 1995;31:13-24.
5. Boelaert JR, Van Landuyt HW, Gordts BZ, De Baere YA, Messer SA, Herwaldt LA. Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients: the effect of nasal mupirocin. Infect Control Hosp Epidemiol 1996;17:809-811.
6. Fernandez C, Gaspar C, Torrellas A, et al. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 1995;35:399-408.
7. Kluytmans JA, Mouton JW, VandenBergh MF, et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996;17:780-785.
8. Perl TM, Cullen JJ, Wenzel RP, et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 2002;346:1871-1877.
9. Cimochowski GE, Harostock MD, Brown R, Bernardi M, Alonzo N, Coyle K. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 2001;71:1572-1579.
10. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999: Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 1999;20:250-278.
11. Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH. Staphylococcus and Micrococcus. In: Doern GV, Ferraro MJ, Gilligan PH, Janda JM, vonGraevenitz A, eds. Manual of Clinical Microbiology. Washington, DC: ASM Press; 1999:264-282.
12. Wittwer CT, Herrmann MG, Moss AA, Rasmussen RP. Continuous fluorescence monitoring of rapid cycle DNA amplification. Biotechniques 1997;22:130-131, 134-138.
13. Martineau F, Picard FJ, Roy PH, Ouellette M, Bergeron MG. Species-specific and ubiquitous-DNA-based assays for rapid identification of Staphylococcus aureus. J Clin Microbiol 1998;36:618-623.
14. Shrestha NK, Tuohy MJ, Hall GS, Isada CM, Procop GW. Rapid identification of Staphylococcus aureus and the mecA gene from BacT/ALERT blood culture bottles using the LightCycler system. J Clin Microbiol 2002;40:2659-2661.
15. Reischl U, Linde HJ, Metz M, Leppmeier B, Lehn N. Rapid identification of methicillin-resistant Staphylococcus aureus and simultaneous species confirmation using real-time fluorescence PCR. J Clin Microbiol 2000;38:2429-2433.
16. Oliveira K, Procop GW, Wilson D, Coull J, Stender H. Rapid identification of Staphylococcus aureus directly from blood cultures by fluorescence in situ hybridization with peptide nucleic acid probes. J Clin Microbiol 2002;40:247-251.
17. Pagano M, Gauvreau K. Principles of Biostatistics. Pacific Grove, CA: Duxbury; 2000:91-99.
18. 2001 Drug Topics Red Book. Montvale, NJ: Medical Economics; 2001:208.
19. Roche Diagnostic Corporation. Indianapolis, IN: Roche Diagnostic; 2002.
20. Allegiance Healthcare Corporation. McGaw Park, IL: Allegiance Healthcare; 2002.
21. Bureau of Labor Statistics. National Compensation Survey. Washington, DC: Bureau of Labor Statistics; 2002. Available at www.bls.gov/ncs/home.htm. Accessed January 26, 2002.
22. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, 2nd ed. Oxford: Oxford Medical Publications; 1997.
23. Johannesson M, Weinstein MC. On the decision rules of cost-effectiveness analysis. Journal of Health Economics 1993;12:459467.
24. Karlsson G, Johannesson M. The decision rules of cost-effectiveness analysis. Pharmacoeconomics 1996;9:113-120.
25. Schmitz FJ, Lindenlauf E, Hofmann B, et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 1998;42:489-495.
26. Watanabe H, Masaki H, Asoh N, et al. Emergence and spread of low-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from a community hospital in Japan. J Hosp Infect 2001;47:294-300.
27. Norazah A, Koh YT, Ghani Kamel A, Alias R, Lim VK. Mupirocin resistance among Malaysian isolates of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2001;17:411-414.
28. Kauffman CA, Terpenning MS, He X, et al. Attempts to eradicate methicillin-resistant Staphylococcus aureus from a long-term-care facility with the use of mupirocin ointment. Am J Med 1993;94:371-378.
29. Annigeri R, Conly J, Vas S, et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001;21:554-559.
30. Hodgson JE, Curnock SP, Dyke KG, Morris R, Sylvester DR, Gross MS. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob Agents Chemother 1994;38:1205-1208.
31. Nunes EL, dos Santos KR, Mondino PJ, Bastos Mdo C, Giambiagi-deMarval M. Detection of ileS-2 gene encoding mupirocin resistance in methicillin-resistant Staphylococcus aureus by multiplex PCR. Diagn Microbiol Infect Dis 1999;34:77-81.